MA48477A - Compositions et méthodes de traitement de la dépression - Google Patents

Compositions et méthodes de traitement de la dépression

Info

Publication number
MA48477A
MA48477A MA048477A MA48477A MA48477A MA 48477 A MA48477 A MA 48477A MA 048477 A MA048477 A MA 048477A MA 48477 A MA48477 A MA 48477A MA 48477 A MA48477 A MA 48477A
Authority
MA
Morocco
Prior art keywords
depression
compositions
treatment
methods
Prior art date
Application number
MA048477A
Other languages
English (en)
Inventor
Thomas N Chase
Kathleen E Clarence-Smith
Original Assignee
Chase Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Therapeutics Corp filed Critical Chase Therapeutics Corp
Publication of MA48477A publication Critical patent/MA48477A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA048477A 2017-04-24 2018-04-23 Compositions et méthodes de traitement de la dépression MA48477A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762489016P 2017-04-24 2017-04-24

Publications (1)

Publication Number Publication Date
MA48477A true MA48477A (fr) 2020-03-04

Family

ID=63919245

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048477A MA48477A (fr) 2017-04-24 2018-04-23 Compositions et méthodes de traitement de la dépression

Country Status (14)

Country Link
US (3) US20200375957A1 (fr)
EP (1) EP3615024B1 (fr)
JP (2) JP7397669B2 (fr)
KR (1) KR102793974B1 (fr)
CN (2) CN110719778B (fr)
AU (2) AU2018258117A1 (fr)
BR (1) BR112019022175A2 (fr)
CA (1) CA3097332A1 (fr)
EA (1) EA201992532A1 (fr)
IL (1) IL270104B (fr)
MA (1) MA48477A (fr)
MX (2) MX2019012594A (fr)
TW (2) TWI843700B (fr)
WO (1) WO2018200387A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3615024B1 (fr) 2017-04-24 2026-02-18 Alto Neuroscience, Inc. Compositions comprenant du pramipexole et d'un antagoniste 5ht3 pour utilisation dans le traitement de la dépression
US20220071976A1 (en) * 2018-12-27 2022-03-10 Chase Therapeutics Corporation Domperidone compositions and methods for treating depression
TW202541796A (zh) * 2023-12-28 2025-11-01 美商查斯治療公司 用於治療失樂症的組成物及方法
WO2025259699A1 (fr) * 2024-06-10 2025-12-18 Alto Neuroscience, Inc. Compositions et procédé de traitement de la dégénérescence rétinienne

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936675A (ja) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3687080T2 (de) 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
DE3885357T2 (de) 1987-06-29 1994-03-24 Duphar Int Res Anellierte Indolderivate.
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
US5364863A (en) 1987-09-08 1994-11-15 Eli Lilly And Company Specific 5-HT3 antagonists
US5223511A (en) 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
CA1304082C (fr) 1987-10-22 1992-06-23 Tetsuya Tahara Composes de la benzoxazine et leurs utilisations pharmaceutiques
AU627221B2 (en) 1988-09-27 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Pyridoindole derivatives and processes for preparation thereof
US5344927A (en) 1989-02-02 1994-09-06 Yamanouchi Pharmaceutical Co., Ltd. Tetrahydrobenzimidazole derivatives and pharmaceutical compositions containing same
CA2030718C (fr) 1989-11-28 1998-05-12 Jacob Berger Composes tricycliques
US5256665A (en) 1991-05-10 1993-10-26 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. Process for preparing new 2-piperazinylbenzimidazole
US5227169A (en) 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5212199A (en) 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
AU3675299A (en) * 1991-06-26 1999-08-19 Sepracor, Inc. Methods and compositions for treating emesis, nausa and other disorders using optically pure R(+) ondansetron
AU2295792A (en) * 1991-06-26 1993-01-25 Sepracor, Inc. Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
US5900250A (en) 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
WO1993023025A1 (fr) 1992-05-13 1993-11-25 Alza Corporation Administration transdermique d'oxybutynine
EP0721348B1 (fr) 1993-09-29 1999-09-01 Alza Corporation Renforcateur de permeation a base de monoglyceride/lactate
US5441740A (en) 1994-05-06 1995-08-15 Longevity Network. Ltd. Cosmetic composition containing alpha hydroxyacids, salicyclic acid, and enzyme mixture of bromelain and papain
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
DE19812413C1 (de) 1998-03-20 1999-06-10 Sanol Arznei Schwarz Gmbh Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend
WO2000006162A1 (fr) * 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Agents a effet antidepresseur, comprenant du pramipexol et un autre antidepresseur
US6136807A (en) 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
US6562368B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
CN1438861A (zh) 2000-04-26 2003-08-27 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
PE20040134A1 (es) * 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
EP1670433B1 (fr) 2003-10-10 2011-11-23 Antares Pharma IPL AG Formulation pharmaceutique transdermique visant a reduire les residus sur la peau
JP4318182B2 (ja) 2005-07-19 2009-08-19 財団法人ヤマハ音楽振興会 端末装置および同端末装置に適用されるコンピュータプログラム
PL1803934T3 (pl) 2005-12-28 2009-03-31 Sensile Pat Ag Mikropompa
CA2651862A1 (fr) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenese induite par le recepteur 5ht
US20080254117A1 (en) 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
CA2698038A1 (fr) 2007-07-26 2009-01-29 Entra Pharmaceuticals Inc. Systemes et procedes d'administration de medicaments
WO2009027564A1 (fr) 2007-08-08 2009-03-05 Legarda Ibanez Juan Jose Utilisation et procédés d'utilisation d'un antagoniste du récepteur (5-ht3) de la sérotonine3 et modulateur sélectif des canaux de chlorure en vue du traitement de l'addiction ou de la dépendance aux médicaments/drogues ou de troubles du système nerveux cent
CA2622696A1 (fr) 2007-11-05 2009-05-05 Diane Mcintosh Methodes et compositions pour retarder le gain de poids associe a l'utilisation de medicaments antipsychotiques atypiques
US8877768B2 (en) 2009-09-18 2014-11-04 Chase Pharmaceuticals Corporation Method and composition for treating alzheimer-type dementia
EP2277123B1 (fr) 2008-04-29 2019-08-07 Roche Diabetes Care GmbH Procédé de sélection de doses de bolus et de motifs d'administration de bolus dans un dispositif d'administration de médicament
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
JP5804951B2 (ja) 2009-01-12 2015-11-04 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 柔軟な特徴部を備える内在の硬いカテーテル及び／又は柔軟なカテーテルアタッチメントの少なくとも１つを有する輸液セット及び／又はパッチポンプ
DE102010034757B4 (de) 2010-08-19 2013-02-14 Prof. Dr. Eduard Heindl Energiespeicher auf Basis von Lageenergie durch hydraulische Hebung einer Felsmasse
US8915879B2 (en) 2010-09-24 2014-12-23 Perqflo, Llc Infusion pumps
EA031156B1 (ru) 2010-12-16 2018-11-30 Суновион Фармасьютикалз Инк. Сублингвальные пленки
WO2012140604A1 (fr) 2011-04-15 2012-10-18 Sandoz Ag Formulations stables de chlorhydrate de pramipexole
WO2013061969A1 (fr) 2011-10-26 2013-05-02 久光製薬株式会社 Préparation à absorption transdermique comprenant une oxybutynine
EP3682871A1 (fr) 2012-03-05 2020-07-22 Becton, Dickinson and Company Dispositif pour détacher des adhésifs
ES2715311T3 (es) 2012-03-19 2019-06-03 Steadymed Ltd Mecanismo de conexión de fluido para bombas tipo parche
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
US20140037713A1 (en) 2012-08-03 2014-02-06 Antares Pharma Ipl, Ag Transdermal compositions for anti-cholinergic agents
JP5270035B1 (ja) 2012-12-06 2013-08-21 久光製薬株式会社 貼付剤及びその製造方法
JP5307931B1 (ja) 2012-12-27 2013-10-02 久光製薬株式会社 貼付剤及びその製造方法
EP3030286B1 (fr) 2013-08-05 2019-10-09 Cam Med LLC Pompe patch moulante
KR20160103548A (ko) * 2015-01-28 2016-09-01 주식회사 제네리스코리아 신경정신계 장애의 치료를 위한 조성물 및 방법
MX389282B (es) * 2017-03-27 2025-03-20 Chase Therapeutics Corp Composiciones y métodos para tratar sinucleinopatías.
EP3615024B1 (fr) 2017-04-24 2026-02-18 Alto Neuroscience, Inc. Compositions comprenant du pramipexole et d'un antagoniste 5ht3 pour utilisation dans le traitement de la dépression
AU2019346543A1 (en) 2018-09-25 2021-05-20 Chase Therapeutics Corporation Composition and use for the treatment of Parkinson's disease and related disorders
WO2020068913A1 (fr) 2018-09-25 2020-04-02 Chase Therapeutics Corporation Combinaisons anti-neurodégénératives et méthodes pour le traitement de maladies neurodégénératives

Also Published As

Publication number Publication date
EP3615024B1 (fr) 2026-02-18
JP2020517670A (ja) 2020-06-18
WO2018200387A1 (fr) 2018-11-01
EP3615024A1 (fr) 2020-03-04
US12521374B1 (en) 2026-01-13
AU2024204179A1 (en) 2024-07-11
IL270104B (en) 2022-07-01
TW202504596A (zh) 2025-02-01
CN110719778B (zh) 2024-06-18
TWI843700B (zh) 2024-06-01
JP2024010018A (ja) 2024-01-23
MX2022013383A (es) 2022-11-30
CA3097332A1 (fr) 2018-11-01
JP7397669B2 (ja) 2023-12-13
EP3615024A4 (fr) 2021-01-20
AU2018258117A1 (en) 2019-12-12
US20200375957A1 (en) 2020-12-03
MX2019012594A (es) 2020-08-03
US20260069573A1 (en) 2026-03-12
CN110719778A (zh) 2020-01-21
BR112019022175A2 (pt) 2020-05-12
IL270104A (fr) 2019-12-31
CN118681024A (zh) 2024-09-24
EA201992532A1 (ru) 2020-04-03
KR20200014289A (ko) 2020-02-10
KR102793974B1 (ko) 2025-04-09
TW201841635A (zh) 2018-12-01

Similar Documents

Publication Publication Date Title
EP3607072A4 (fr) Compositions et méthodes de traitement de la phénylcétonurie
EP3687981A4 (fr) Compositions et méthodes de traitement du cancer
MA46102A (fr) Composés de tétracycline et méthodes de traitement
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
EP3634442A4 (fr) Méthodes de traitement et de prévention de maladies
EP3454945A4 (fr) Inhibiteurs de ash1l et méthodes de traitement au moyen de ceux-ci
MA52790A (fr) Compositions et méthodes de traitement de la thrombopénie immune
EP3442515A4 (fr) Préparation liposomale et méthodes de traitement
EP3658139A4 (fr) Méthodes de traitement de maladies hépatiques
EP3519058C0 (fr) Compositions et méthodes de traitement des cheveux
EP3983445A4 (fr) Compositions et méthodes de traitement du cancer
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
EP3658142A4 (fr) Compositions et méthodes de traitement de la galactosémie
EP3373962A4 (fr) Compositions et méthodes de traitement de maladies auto-immunes et de cancers
EP3458159A4 (fr) Compositions et méthodes de prévention et de traitement myopathies mitochondriales
EP3621593A4 (fr) Compositions pharmaceutiques et méthodes de traitement de maladies cardiovasculaires
EP3713583A4 (fr) Méthodes et compositions pour le traitement de la peau
EP3691649A4 (fr) Compositions et méthodes de traitement des plaies
EP3313186A4 (fr) Combinaison d'inhibiteurs de lpt-723 et de point de contrôle immunitaire et méthodes de traitement
EP3298141A4 (fr) Compositions et méthodes de traitement du cancer
EP3328372A4 (fr) Compositions et méthodes de traitement du cancer
EP3599983A4 (fr) Endoscopes et méthodes de traitement
EP3386507A4 (fr) Méthodes et compositions de traitement des ulcères gastriques
EP3352729A4 (fr) Méthodes et compositions de traitement de la peau
EP3615024A4 (fr) Compositions et méthodes de traitement de la dépression